Saltar al contenido
Merck

Oral locally active steroids in inflammatory bowel disease.

Journal of Crohn's & colitis (2012-07-13)
Tiago Nunes, Manuel Barreiro-de Acosta, Ignácio Marin-Jiménez, Pilar Nos, Miquel Sans
RESUMEN

IBD is a chronic and relapsing inflammatory disorder of the gut that demands long-lasting treatment targeting both flare-up periods and maintenance of remission. Oral systemic steroids have been used to induce remission in patients with active IBD for over 50 years due to their potent anti-inflammatory effects. The efficacy of systemic steroids in this setting has been largely demonstrated. However, the wide range of adverse events associated with these drugs has prompted the development of equally effective but less toxic steroid compounds. Currently, topically acting oral steroids are an important therapeutic option for Crohn's disease, ulcerative colitis and microscopic colitis, being oral budesonide and oral beclomethasone established elements of the IBD armamentarium. At present, oral budesonide is the first-line therapy to induce remission in microscopic colitis and mild to moderate ileocaecal CD patients and oral beclomethasone is effective treating mild to moderate UC patients with left-sided or extensive disease. This review aims at evaluating the current role of these compounds in IBD clinical practice.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Beclomethasone, ≥99%
Supelco
Beclomethasone dipropionate, analytical standard, for drug analysis
Beclomethasone dipropionate, anhydrous, European Pharmacopoeia (EP) Reference Standard